The　relevant　mechanism　of　tumor-associated　macrophages　(TAMs)　in　the　treatment　of　colorectal　cancer　patients　with　immune　checkpoint　inhibitors　(ICIs)　is　discussed,　and　the　application　prospects　of　TAMs　in　reversing　the　treatment　tolerance　of　ICIs　are　discussed　to　provide　a　reference　for　related　studies.　As　a　class　of　drugs　widely　used　in　clinical　tumor　immunotherapy,　ICIs　can　act　on　regulatory　molecules　on　cells　that　play　an　inhibitory　role　-　immune　checkpoints　-　and　kill　tumors　in　the　form　of　an　immune　response　by　activating　a　variety　of　immune　cells　in　the　immune　system.　The　sensitivity　of　patients　with　different　types　of　colorectal　cancer　to　ICI　treatment　varies　greatly.　The　phenotype　and　function　of　TAMs　in　the　colorectal　cancer　microenvironment　are　closely　related　to　the　efficacy　of　ICIs.　ICIs　can　regulate　the　phenotypic　function　of　TAMs,　and　TAMs　can　also　affect　the　tolerance　of　colorectal　cancer　to　ICI　therapy.　TAMs　play　an　important　role　in　ICI　resistance,　and　making　full　use　of　this　target　as　a　therapeutic　strategy　is　expected　to　improve　the　immunotherapy　efficacy　and　prognosis　of　patients　with　colorectal　cancer.